Breast-cancer screening--viewpoint of the IARC Working Group.

  title={Breast-cancer screening--viewpoint of the IARC Working Group.},
  author={B{\'e}atrice Lauby-Secretan and Chiara Scoccianti and Dana Loomis and Lamia Benbrahim-Tallaa and V{\'e}ronique Bouvard and Franca Bianchini and Kurt Straif},
  journal={The New England journal of medicine},
  volume={372 24},
The International Agency for Research on Cancer (IARC) has updated its 2002 guidelines on screening for breast cancer, drawing on data from studies completed in the past 15 years. 

Tables from this paper

Breast cancer screening: Impact on care pathways

Controversy persists concerning screening programs, related to a potential risk of overdiagnosis or the impact on survival, and the aggressiveness of the related treatments.

Benefit and Risks of Screening for Breast Cance r

This data indicates that among women diagnosed with breast cancer in industrialized countries, non- Hodgkin's lymphoma is the second most frequent cause of death and the most common type of cancer in women living in these countries is BC.

Targeting breast cancer outcomes‐what about the primary relatives?

Up to 65% of newly diagnosed breast cancer patients had not been screened correctly before diagnosis resulting in increased stage of cancer at presentation, and whether their primary relatives are assessed appropriately is assessed.

Impact of chronic diseases on effect of breast cancer screening

The impact of health status on the effect of breast cancer screening is investigated and subgroups of women may benefit differently.

Training health workers in clinical breast examination for early detection of breast cancer in low‐ and middle‐income countries

This is a protocol for a Cochrane Review to assess whether training in CBE improves the ability of health workers in LMICs to detect early breast cancer.

Screening for cancers with a good prognosis: The case of testicular germ cell cancer

To determine, using testicular germ cell cancer screening as an example, whether screening can also be effective for cancers with a good prognosis.

The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

The risk of breast and ovarian cancer among women with mutations such as BRCA1 and BRCA2 mutations can be mitigated by operations to remove the organs at greatest risk. Data are presented to assist

An active surveillance program in oral preneoplasia and translational oncology benefit

This review examined whether there is a need to establish an active surveillance clinic for head and neck cancer in this region or whether such a clinic should be established in the future.

Breast Cancer Detection and Diagnosis Using AI

This chapter focuses on various imaging techniques and stages for the detection and diagnosis of breast cancer with its benefits and risks.

Cancer prevention as part of precision medicine: ‘plenty to be done’

No country can afford to treat its way out of the cancer problem, and opportunities for prevention and early detection, including precision prevention based on recent advances in cancer biology are described.



Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program

This is the first report using individual‐based data on invitation and participation to analyze breast cancer mortality among screened and nonscreened women in the Norwegian Breast Cancer Screening Program.

Priorities for the primary prevention of breast cancer

The underutilization of chemoprevention in high‐risk women, the additional advances that could be made by including young women in prevention efforts, and how the molecular heterogeneity of breast cancer affects prevention research and strategies are discussed.

Summary of the Evidence of Breast Cancer Service Screening Outcomes in Europe and First Estimate of the Benefit and Harm Balance Sheet

  • E. Paci
  • Medicine, Political Science
    Journal of medical screening
  • 2012
The chance of saving a woman's life by population-based mammographic screening of appropriate quality is greater than that of over-diagnosis, and service screening in Europe achieves a mortality benefit at least as great as the randomized controlled trials.

A population-based case-cohort evaluation of the efficacy of mammographic screening for breast cancer.

Case-cohort methodology can be used to perform efficient assessment of screening efficacy in large cohorts, while eliminating or controlling for sources of bias, as illustrated in this paper.

Efficacy of breast cancer screening in the community according to risk level.

In this community-based study, screening history was not associated with breast cancer mortality, and potential limitations of this study argue for a cautious interpretation of these findings.

Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme

Fourteen years after the introduction of a screening programme, a major reduction in breast cancer mortality has been observed, with the largest reduction in the 50–69 years age group showing the largest decrease.

Effect of screening mammography on breast-cancer mortality in Norway.

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.

Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review

The most plausible estimates of overdiagnosis range from 1% to 10%, and substantially higher estimates reported in the literature are due to the lack of adjustment for breast cancer risk and/or lead time.

Breast cancer incidence and mortality in the breast cancer detection demonstration project [published errtum appears in J Natl Cancer Inst 1989 Oct 4;81(19):1513].

Breast cancer incidence and mortality were lower for women who entered the BCDDP for routine screening than they were forWomen who entered for a reason such as concern about breast disease, family history of breast cancer, or a physician's recommendation.